Author: Andy Smith
The CEOs of seven big pharmaceutical companies recently appeared before Congress to discuss the prices they charge for their drugs. Their appearance comes at a time when President Trump and members of Congress continue to raise the issue of high drug prices. In this report we seek to add a little clarity on this area which is both complex and likely to remain an issue throughout the 2020 US presidential campaign.
A complex issue added to fragmented healthcare systems
Investors in biotech and pharma companies would clearly like the revenues of their companies to grow at a rate higher than inflation, particularly in a drug’s launch phase. However, in a bid to boost profits, some companies have acquired drugs without incurring the cost of their development and immediately increased the price by up to 5,000%. Doctors treating cancer patients in the US have coined the phrase ‘financial toxicity’ in response to the finding that two years after a cancer diagnosis, 42.4% of US cancer patients had depleted their entire life’s assets. In this article, we look at some of the dynamics of drug pricing and reimbursement across Europe and the US, the markets that do and do not allow free pricing, and the influence of co-pays, coinsurance and high deductibles in the US. We start with some definitions of drug pricing and how recent events have brought this into focus.
There are many drug prices
In all markets, there is more than one drug price. This starts with the list or gross price that the manufacture determines at launch. In some free-pricing markets like the US and Germany, payers for the drug may or may not be consulted before launch but in many others access to that market will hinge on a negotiated list price for national access with additional discounts determining the net price which can vary regionally. Once the drug starts its journey on the pharmaceutical value chain, the price of the product can rise and fall before it is eventually linked to a prescription. Even after the physician writes a prescription, in the US, the amount that a patient has to pay and the rebates that flow back through the pharmaceutical value chain continue to resonate after the patient receives the drug.
- Patients: in the US, their position could not get much worse
- Pharmaceutical and biotech companies such as AstraZeneca, GSK or Pfizer
Likely losers from regulatory change
- US pharmacy benefit managers (PBMs) if rebates are eliminated
- US health insurance companies
Winners and losers: The companies shown above do not translate into buys and sells as other themes (and valuation parameters) may conflict with this one
What’s in a price?
This is not an easy question to answer because the benefits or value of a drug, the available healthcare budget and the drug’s impact on a healthcare system all need to be considered when determining the price that the drug can command in negotiations between manufacturers and payers. Payers can be national or regional (and even in the UK, there are both) and in the US there is a highly fragmented and interconnected mix of public and private payers.
For any given drug, there are a number of prices – the list (or gross) price is the one that is made public and in recent times, the one that many big pharmaceutical companies have been increasing once or twice a year by about 9% in the US. The list price is frequently much higher than the price that payers pay, whether the payer is the NHS in the UK or a health insurance company in the US, but not if, as in some countries, the patient pays directly. In the recent congressional testimony, the seven pharmaceutical CEOs were at pains to point out that while list prices have been increasing, the net prices (that they receive) have been falling. The net price includes any rebates, subsidies and discounts paid to intermediaries such as wholesalers and PBMs in the pharmaceutical value chain. These typically reduce the net price to between 40% and 65% of the list price. The net price is rarely (if ever) quoted and can only be found out by asking payers. Between the list and net prices are a number of equally opaque prices that the payer or patient will not be aware of, but these prices follow the drug on its journey from manufacturer, wholesaler, pharmacy and even physician practice, to the patient.
In the US the price can also be influenced by the organisations found towards the end of this journey along the pharmaceutical value chain, or even after the patient receives the drug. These commercial influences are from PBMs or the patients’ health insurance companies (that administer the health plans of a majority of US patients, and are funded by the premiums paid by the employee and employer) and, to a much lesser extent, the Federal health programs may have already decided whether a patient can receive a branded or generic form of a drug before they are diagnosed. At each step in a drug’s journey along the value chain, the prices paid between manufacturers, wholesalers and pharmacies can rise and fall and can include, for example, the average selling price or the wholesaler acquisition cost. Furthermore, at the patient end of the US value chain, depending on whether the patient has private health insurance or is covered by the public or Federal health programs (Medicare, Medicaid or veterans administration or VA), there are other payments, either regular, variable or one-off, that a patient may need to pay before they can receive their medicine. US patients with so-called high-deductible health insurance plans (with low annual premiums) pay out-of-pocket costs including close-to-list drug prices of up to $6,550 per year before their health insurance starts to cover their healthcare costs. Typically, these plans encourage patients to shop around for their drugs although the imposition of a lower price cap on out-of-pocket costs was proposed during the recent congressional hearing.
US congress weighs in on drug pricing
Top pharmaceutical company executives prepares to testify before the US Senate Finance Committee hearing on drug prices. Photo by Pablo Martinez Monsivais
The answer is that there is such a substantial pricing differential between a high-volume small molecule generic drug, where pricing is literally pennies, and a recently approved very low volume large molecule (which is much more expensive to make) and is the first available treatment for that condition. The latter is either the typical orphan drug profile (to treat rare diseases) or a drug to treat cancer (one of the six protected Medicare drug classes in the US, which partly explains the higher prices for oncology drugs in the US compared to other markets). Orphan drugs and newer oncology drugs, whether they are small or large molecules, can have prices in the hundreds of thousands of dollars. In the past, these low volume specialist drugs for orphan diseases or the newest oncology drugs made up such a small part of the drugs budget that their impact was low and US insurance companies would cover patients with those diseases to increase the attractiveness of their health plans. Part of the drug pricing problem is the increasing number of high-value indications that are driving the US drug budget. However, the recent testimony from the pharmaceutical CEOs to Congress has centered on the role of the intermediaries between the drug manufacturers and the patients in making drugs more expensive. There is some truth in this as the CEO from one of the companies in the congressional hearings described the intense price competition between the three main branded insulin suppliers in the US. As a result of this competition the net price has fallen by 30% since 2012 with a consequential impact on insulin revenues. Despite this fall in net prices, the out-of-pocket costs to patients have increased by 60%. This has been associated with the deaths of US diabetic patients who were unable to afford their insulin injections. The cause of these increased list prices, while net insulin prices have been falling, has been laid at the door of the for-profit PBMs who retain a portion of the rebates that are meant for insurers, patients and manufacturers.
There is a profit motive linking list and net prices as the higher the list price, the higher the return to the participants in the channel, irrespective of what the final price net of rebates is to the manufacturer. In US hospitals, the structural issues of the mixed public/private healthcare system also compound these drug pricing issues as hospitals mark-up the list prices of the drugs their pharmacy dispense (having been acquired at a net price) by up to 500%. In addition, for products like oncology drugs that are administered in a physician’s office or outpatient clinic under Medicare Part B in the US, the practice can currently charge the average selling price plus 6% (regardless of the net price paid). For patients with private insurance, these inflated drug prices may be invisible and negotiated down slightly but are ultimately paid for by increasing premiums.
It is no surprise therefore that the US Department of Health and Human Sciences (HHS) has proposed the elimination of rebates in order to lower the price of drugs that patients pay. The HHS proposals only apply to the Medicare Part D prescription drug benefit outside hospitals and outpatients (which is about 29% of all US retail drug spend), but the pharmaceutical CEOs who recently appeared before Congress were broadly supportive of this proposal. A more recent point of contention is at what point, and how much, of the rebates are passed onto patients. If rebates were passed on at the pharmacy counter rather than reducing list prices, the channel participants like the PBMs would retain the ability to determine formulary placement on the basis of (perhaps additional) rebates.
What is reimbursement?
The drug pricing issues in the US are also partially brought about by it being a market where the manufacturer is free to set a (list) price at launch. Germany is also a free pricing market, but only for the first year after launch. In most other high-income countries, the drug is only allowed to access that market at a price determined by a negotiation with the payer. Reimbursement is therefore the negotiation of a price between manufacturer and payer that allows the manufacturer access to that market. For single-payer markets like the NHS in England, its benefits and risks of a drug are appraised by a separate body – the National Institute for Health and Care Excellence, or NICE. NICE reviews the clinical and other data prepared by the manufacture in a submission that is generically called a health technology assessment (HTA) and decides whether NHS England should reimburse the drug. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. There have been some high-profile failures, not of a drug in clinical trials, but in the negotiation of the price that the NHS should pay in order to access the UK market. The manufacture of the disease-modifying drugs to treat the orphan disease cystic fibrosis is currently at such an impasse after NICE failed to recommend it for reimbursement in England.
In other European markets and even the UK and the US, national reimbursement is only the first step after which more regional negotiations, even down to the individual hospital group level are required for the drug to be included in, for example, a hospital’s or an insurer’s formulary. At the individual hospital or health insurer level, the clinical and outcome data will again be reviewed and if there is more than one manufacturer for a similar drug, a tender or contracting process can bring the net price down even further. All these discussions are confidential and there may be many net prices for a single drug. Without conducting primary market research with payers, the resulting net prices will never be known.
Most biotech and pharma companies launch their products in the US because of its size, the free pricing aspect and because over two thirds of people in the US have private health insurance. This means that the US has higher drug prices than most countries, which has emerged as a point of contention in the drug pricing debate. One often purported remedy for this price differential is to import drugs from lower-priced markets like Canada or Mexico. Other much smaller single-payer markets like the UK have been accused of ‘freeloading’ or benefitting from the US subsidising its high drug prices. US President Trump has proposed referencing US drug prices to an index of prices paid in other markets but only for the drugs administered under Medicare Part B (outpatient and physician office administration of drugs to the over-65s). Under Federal law in the US, Medicare is prohibited from negotiating the prices of the drugs it buys from manufacturers but relies on the negotiations of the many private health insurers who provide the part-privatised Medicare Part D plans. Other parts of the Federal health programs do have lower drug prices than, for example, Medicare Part D, as the VA requires that manufacturers charge them the lowest price paid in the private sector.
Ironically, drug price referencing is not new and is one of the most common payer pricing approaches globally. Even payers in the US will reference the price of the standard of care that probably comprises cheap generic drugs, to the proposed price of a new drug for the same indication to determine whether the additional value of the new drug can be justified. However, the most common use of price referencing is in southern Europe where countries will determine the price they will pay for a drug from an average of the lowest prices paid in other European countries.
Conclusion: No quick fixes
The price that a manufacturer charges for its drug is a balance between the costs of the drug’s development, the associated failures of that company’s other drugs, and the sales and earnings expectations of the company’s investors. In addition, a further tension exists between payers with limited budgets, but their need to provide an adequate standard of care for their patients. Add to this the fragmented nature of the US healthcare system, global price differentials and, like Brexit, you have a range of issues that have developed over the years that have no single easy fix. The drug pricing debate will therefore continue.
General disclaimer and copyright
This report has been prepared and issued by Edison. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the Edison analyst at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.
No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.
Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison’s policies on personal dealing and conflicts of interest.
Copyright: Copyright 2019 Edison Investment Research Limited (Edison). All rights reserved FTSE International Limited (“FTSE”) © FTSE 2019. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.
Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd who holds an Australian Financial Services Licence (Number: 427484). This research is issued in Australia by Edison AU and any access to it, is intended only for “wholesale clients” within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.
The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.
Neither this document and associated email (together, the “Communication”) constitutes or form part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Any decision to purchase shares in the Company in the proposed placing should be made solely on the basis of the information to be contained in the admission document to be published in connection therewith.
This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “FPO”) (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document (nor will such persons be able to purchase shares in the placing).
This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.
The Investment Research is a publication distributed in the United States by Edison Investment Research, Inc. Edison Investment Research, Inc. is registered as an investment adviser with the Securities and Exchange Commission. Edison relies upon the “publishers’ exclusion” from the definition of investment adviser under Section 202(a) (11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.</small
|Frankfurt +49 (0)69 78 8076 960
|London +44 (0)20 3077 5700
280 High Holborn
London, WC1V 7EE
|New York +1 646 653 7026
1,185 Avenue of the Americas
3rd Floor, New York, NY 10036
United States of America
|Sydney +61 (0)2 8249 8342
Level 4, Office 1205
95 Pitt Street, Sydney
NSW 2000, Australia